Salarius Pharmaceuticals shares are trading lower after the company was notified by MD Anderson Cancer Center of a Grade 4 adverse event in the Seclidemstat clinical trial. The FDA has placed the trial on partial clinical hold, preventing new patient enrollment while allowing current patients to continue treatment.
$SLRX
Biotechnology: Pharmaceutical Preparations
Health Care
Salarius Pharmaceuticals shares are trading lower after the company was notified by MD Anderson Cancer Center of a Grade 4 adverse event in the Seclidemstat clinical trial. The FDA has placed the trial on partial clinical hold, preventing new patient enrollment while allowing current patients to continue treatment.